Elevance Health (NYSE:ELV) Price Target Raised to $357.00

Elevance Health (NYSE:ELV) had its target price hoisted by analysts at Leerink Partners from $350.00 to $357.00 in a note issued to investors on Thursday,MarketScreener reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners’ price objective would suggest a potential upside of 3.41% from the company’s current price.

Other equities analysts have also issued reports about the stock. Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a research report on Thursday, January 8th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Barclays set a $393.00 price objective on Elevance Health in a report on Friday. Finally, The Goldman Sachs Group initiated coverage on Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $398.16.

Elevance Health Stock Performance

ELV traded down $1.76 during trading on Thursday, hitting $345.22. 199,515 shares of the company traded hands, compared to its average volume of 1,676,695. The firm has a market cap of $76.72 billion, a P/E ratio of 13.69, a price-to-earnings-growth ratio of 1.86 and a beta of 0.51. The company has a quick ratio of 1.56, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health has a one year low of $273.71 and a one year high of $458.75. The stock’s fifty day moving average is $351.21 and its 200 day moving average is $328.99.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health will post 33.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Elevance Health

Several institutional investors have recently modified their holdings of ELV. Nilsine Partners LLC lifted its stake in Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after purchasing an additional 29 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in shares of Elevance Health by 3.0% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares during the period. Fulton Breakefield Broenniman LLC increased its stake in Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after buying an additional 29 shares during the period. Perigon Wealth Management LLC boosted its position in Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after buying an additional 29 shares during the period. Finally, Savvy Advisors Inc. increased its position in shares of Elevance Health by 3.2% during the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after acquiring an additional 30 shares during the period. 89.24% of the stock is owned by institutional investors.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat and strong Carelon performance: ELV reported quarterly EPS above consensus and rising premiums with Carelon revenue growth, driving the immediate bullish reaction. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Analyst sentiment and dividend hike support investor confidence: Brokerages maintain a generally constructive view (“Moderate Buy”) and the company raised its quarterly dividend slightly, supporting income-oriented investors.
• Neutral Sentiment: Short-term technical/mean-reversion signal noted: Some analysts point to a historically bullish signal after the recent extreme moves, suggesting potential for a bounce but also highlighting continued volatility. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: 2026 profit guidance below Street expectations and flagged revenue decline: Management’s FY‑2026 guidance and commentary signaled lower profit and a revenue headwind next year, which caps upside from the beat and is a key reason investors trimmed positions. Elevance forecasts 2026 profit below estimates, flags revenue decline
• Negative Sentiment: Medicare Advantage rate proposal and membership/margin pressures are headwinds: CMS’s proposed ~0.09% MA rate increase for 2027 and ongoing membership shifts and higher medical expenses are pressuring margins and the 2026 outlook. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts Shape 2026 Outlook

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.